209 related articles for article (PubMed ID: 37072750)
1. Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
Hui P; Ni F; Zheng L; Jia L; Wang Z
BMC Cancer; 2023 Apr; 23(1):355. PubMed ID: 37072750
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
Front Immunol; 2022; 13():951455. PubMed ID: 36189298
[TBL] [Abstract][Full Text] [Related]
3. Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.
Liu J; Zhang Z; Liu X; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
World J Surg Oncol; 2022 Feb; 20(1):47. PubMed ID: 35209909
[TBL] [Abstract][Full Text] [Related]
4. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
Fan CN; Ma L; Liu N
J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
[TBL] [Abstract][Full Text] [Related]
5. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
7. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
[TBL] [Abstract][Full Text] [Related]
8. Identification of a prognosis-related ceRNA network in cholangiocarcinoma and potentially therapeutic molecules using a bioinformatic approach and molecular docking.
Gao X; Zhang W; Jia Y; Xu H; Zhu Y; Pei X
Sci Rep; 2022 Sep; 12(1):16247. PubMed ID: 36171401
[TBL] [Abstract][Full Text] [Related]
9. Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer.
Wang J; Shen C; Dong D; Zhong X; Wang Y; Yang X
Int Immunopharmacol; 2021 Jan; 90():107146. PubMed ID: 33189610
[TBL] [Abstract][Full Text] [Related]
10. A Competing Endogenous RNA Network Reveals Novel lncRNA, miRNA and mRNA Biomarkers With Diagnostic and Prognostic Value for Early Breast Cancer.
Luo ZB; Lai GE; Jiang T; Cao CL; Peng T; Liu FE
Technol Cancer Res Treat; 2020; 19():1533033820983293. PubMed ID: 33371806
[TBL] [Abstract][Full Text] [Related]
11. Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Yu Y; Zhang W; Li A; Chen Y; Ou Q; He Z; Zhang Y; Liu R; Yao H; Song E
JAMA Netw Open; 2020 Apr; 3(4):e202149. PubMed ID: 32259264
[TBL] [Abstract][Full Text] [Related]
12. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.
Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517
[TBL] [Abstract][Full Text] [Related]
13. A hypoxia related long non-coding RNA signature could accurately predict survival outcomes in patients with bladder cancer.
Zhang F; Wang X; Hu H; Yang Y; Wang J; Tang Y; Li D; Bai Y; Han P
Bioengineered; 2021 Dec; 12(1):3802-3823. PubMed ID: 34281486
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
15. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
Bai Y; Zhang Q; Liu F; Quan J
Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
[TBL] [Abstract][Full Text] [Related]
16. A new risk model based on a 11-m
Lei L; Li N; Yuan P; Liu D
BMC Cancer; 2022 Apr; 22(1):365. PubMed ID: 35382776
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel MSI-related ceRNA network for predicting the prognosis and immunotherapy response of gastric cancer.
Zhang L; Cao L; Liu J; Duan L; Zhou W; Li T; Guan L; Wu X; Zhang H
Aging (Albany NY); 2023 Jun; 15(11):5164-5189. PubMed ID: 37310469
[TBL] [Abstract][Full Text] [Related]
18. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.
Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M
Front Immunol; 2023; 14():1279789. PubMed ID: 37928532
[TBL] [Abstract][Full Text] [Related]
19. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
20. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]